Bioanalytical Systems Cultura da Companhia

Ms. Jill C. Blumhoff has been Chief Financial Officer and Vice President of Finance at Bioanalytical Systems Inc. since May 9, 2016. Ms. Blumhoff served as Director of Finance and IT at Bioanalytical Systems Inc. since September 24, 2015 until May 9, 2016. Ms. Blumhoff received a Bachelor of Science degree in accounting from the University of the Illinois at Urbana-Champaign in 1998.

Mr. Philip A. Downing, B.A. has been Senior Vice President of Preclinical Services at Bioanalytical Systems, Inc. since March 8, 2017 and serves as its Acting Principal Executive Officer. Mr. Downing served as Vice President of Preclinical Services at Bioanalytical Systems, Inc. since March 17, 2015 until March 8, 2017. Mr. Downing served as Senior Director of Preclinical Services of Bioanalytical Systems Inc. until March 17, 2015. Mr. Downing has extensive experience designing and testing pre-clinical dosing formulations and has achieved success in securing an extensive client base for preclinical and clinical service needs. He served as General Manager of Preclinical Services at Bioanalytical Systems Inc. He started at BASi as an Analytical Chemist more than 10 years ago. With his talent, he moved into leadership positions such as Director of Analytical Services and Assistant General Manager, until reaching his present position as General Manager. He worked for a clinical research facility, GFi Pharmaceuticals (now Covance Labs) as an Analytical Scientist and RSO designing and validating radiolabeled and non-radiolabeled assays used to support clinical ADME studies. He received a B.A. in Chemistry and Biology from the Indiana University.

Dr. Peter T. Kissinger, also known as Pete, Ph.D. has been Scientific Advisor of Bioanalytical Systems, Inc. since May 1, 2017. Dr. Kissinger serves as Scientific Advisor of Shantani Proteome Analytics Pvt. Ltd. In 2007, Dr. Kissinger co-founded Phlebotics, Inc., and serves as its Chairman and Acting Chief Executive Officer. He served as the Chief Executive Officer of Prosolia, Inc. from 2005 to October 2010. Dr. Kissinger founded Bioanalytical Systems Inc. (BASi) in 1974 and served as its Executive Chairman since 1974. He served as Chief Executive Officer and President at Bioanalytical Systems, Inc. from 1974 to August 25, 2006 and also served as its Chief Scientific Officer from September 27, 2006 to August 28, 2007. He is a highly recognized pioneer in hydrodynamic techniques for the neurosciences, modern liquid chromatography and in vivo methodology for drug metabolism. He served as an Executive Director of Bioanalytical Systems Inc. since 1974. He was a Founder of the first Purdue new business incubator, INventure, in the late 1980s. He served as the President and Chief Executive Officer of AAA Foundation for Traffic Safety. He serves as the Chairman of Tienta Sciences, Inc. Dr. Kissinger serves as the Chairman Emeritus of Bioanalytical Systems, Inc. He served as the Chairman at Prosolia, Inc. since October 2010 and has been its Director since October 2010. He has been a Director of Chembio Diagnostics, Inc. since June 2011. He serves as a Director of S2w, Inc. He serves on the boards of the Indiana Health Industry Forum; and Tymora, a recent Purdue-based startup company. He serves as a Part-time Professor of Chemistry at Purdue University, where he has been teaching since 1975. He is a columnist for the trade publication Drug Discovery News. He served as a Research Associate at the University of Kansas from 1970 to 1972 and an Assistant Professor at Michigan State University from 1972 to 1975. Dr. Kissinger's academic research involved the development of modern liquid chromatography techniques and in vivo methodology for drug metabolism and the neurosciences. He has presented more than 400 invited lectures. He has published more than 240 scientific papers and is a Fellow of the American Association of Pharmaceutical Scientists and the American Association for the Advancement of Science. He was a finalist for Ernst & Young Entrepreneur of the Year Award in the Indiana Heartland region for 2001 and 2002. He is the recipient of the Outstanding Commercialization Award for Purdue University Faculty. Dr. Kissinger has a Bachelor of Science degree in Chemistry from Union College in 1966 and a Doctorate in Analytical Chemistry from the University of North Carolina in 1970.

Dr. James Sevall Bourdage has been Vice President of Bioanalytical Operations at Bioanalytical Systems Inc. since June 2, 2014. Dr. Bourdage served as the Vice President of Operations at Bioanalytical Systems Inc. since June 2, 2014. Dr. Bourdage served as an Executive Director Biopharmaceutical CMC Solutions at Covance Inc., Greenfield, Indiana, since 2011, where he was responsible for the US Biotechnology CMC operation of this $2.4 billion drug development services organization. He served as Senior Director of Bioanalytical Sciences, at Pharmathene, Inc., Annapolis, Maryland, a biodefense company with more than $300 million in government contracts. From 2003 to 2009, Dr. Bourdage was Global Research Advisor and Team Leader, Laboratory for Experimental Medicine at Eli Lilly Co., Indianapolis, where his responsibilities included oversight of biotherapeutic immunogenicity and biomarker assay development to support global clinical trials. Previously, he was Senior Research Scientist, Drug Absorption and Transport at Pharmacia (Upjohn), Kalamazoo, Michigan, where he received the Upjohn Corporate Special Recognition Award in 1992 and the Quality Control Achievement Award in 1993. Dr. Bourdage received a Ph.D. in Immunochemistry from the University of Illinois in 1979. He is a member of the American Society of Clinical Pathologists and the American Association of Pharmaceutical Scientists and is the author of numerous scientific papers.